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in type 2 diabetes mellitus patients  
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ABSTRACT
Introduction. Neuropathies in type 2 diabetes mel-
litus (T2DM) patients are well known. However, elec-
trophysiological changes in their peripheral nerves, 
particularly before overt peripheral neuropathy have 
received much less attention. Hence, we aimed to 
study the electrophysiological status of bilateral sural 
nerves in T2DM patients who do not show symptoms 
and signs of peripheral neuropathy.
Material and methods. We selected 35 T2DM male 
patients and 35 age- and sex-matched control subjects 
without any clinical evidence of peripheral neuropathy 
and infectious, systemic, metabolic, and neuropsychi-
atric illnesses after informed written consent. Nerve 
conduction study (NCS) of bilateral sural nerves of 
both the groups was done at the lab temperature of 
26 ± 2ºC by antidromic method of stimulation using 
standard methods. Their latency, conduction velocity, 
amplitude, and duration of bilateral sural sensory 
nerve action potentials (SNAPs) were measured and 
compared. 
Results. T2DM patients had reduced amplitudes of 
bilateral sural SNAPs compared to control subjects 
[left (12.46 ± 3.77) μV vs. (16.42 ± 4.58) μV, p = 0.000; 
right (11.96 ± 4.45) μV vs. (16.62 ± 6.20) μV, p = 0.001] 
though they were above the normal cut-off value of 
≥ 4 μV. T2DM patients showed prolonged durations of 
bilateral sural SNAPs compared to the control subjects 
[left (1.99 ± 0.38) ms vs. (1.67 ± 0.27) ms, p = 0.000; 
right (1.92 ± 0.47) ms vs. (1.55 ± 0.33) ms, p = 0.000].
Conclusion. Reduced amplitudes and prolonged dura-
tions of bilateral sural SNAPs are the electrophysiologi-
cal alterations, suggestive of peripheral neuropathy, in 
T2DM patients that appear before they show clinical 
symptoms and signs of peripheral neuropathy. (Clin 
Diabetol 2017; 6, 4: 126–130)
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Introduction
Diabetic neuropathy can involve any peripheral 
nerve and is one of the major causes of morbidity 
among diabetes patients. Distal symmetric poly-
neuropathy is the most common form of diabetic 
neuropathy. The most frequent presentation includes 
distal sensory loss, though numbness, tingling, 
sharpness, or burning sensations that begin in the 
feet and spreads proximally. However, up to 50% of 
patients do not have symptoms of neuropathy [1]. 
Some studies have reported the evidences of central 
neuropathy in T2DM patients, though the patients do 
not have symptoms of central nervous system (CNS) 
impairment [2–5].
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Peripheral neuropathies are important complica-
tions of diabetes mellitus associated with sensory loss, 
pain, and may be weakness [6]. Electrophysiological 
investigations are sensitive in determining peripheral 
and central neuropathy in diabetes patients. Nerve con-
duction study (NCS) and electromyography (EMG) are 
frequently used to diagnose the disorders of peripheral 
nervous system (PNS) [7]. In practice, these electro-
physiologic studies serve as an extension of the clinical 
examination. NCS is essential in the diagnosis of focal 
neuropathies and diffuse polyneuropathies [8]. These 
studies are also an accurate and non-invasive method 
of evaluating the status of the peripheral nerves [9].
Sural nerve (short saphenous nerve) is the only pure 
sensory nerve in the leg, which is tested routinely. It 
supplies the branches to the skin on the back of the leg 
and then continues as lateral dorsal cutaneous nerve 
along the outside of the foot and little toe. Routine NCS 
includes motor nerve conduction velocity (NCV), sen-
sory nerve action potential (SNAP), F-wave study, and 
H-reflex. Although the NCS complement one another, 
each yields different information. Diabetic neuropathy 
that most frequently present with distal sensory loss 
is one of the most common indications for NCS [10].
Sensory NCS is integral of any electrophysiological 
evaluation because they are more sensitive than mo-
tor NCS in detection of early or mild disorders [11]. 
A compound potential that represents the summation 
of all the individual sensory fiber action potentials is 
the sensory nerve action potential (SNAP). SNAPs are 
usually biphasic or triphasic potentials [12].
Abnormalities within the PNS in T2DM patients 
are well documented. However, the electrophysi-
ological changes in the PNS, particularly before the 
development of the symptoms in them, have received 
much less attention. Hence, in this study, we studied 
electrophysiological status of bilateral sural nerves in 
T2DM patients who do not have clinical evidence of 
peripheral neuropathy and subjects with normal sural 
SNAPs were included as the study population. 
Materials and methods
This was a comparative cross-sectional study done 
at B.P. Koirala Institute of Health Sciences (BPKIHS), 
Nepal with approval from the ethics committee. Thirty-
five T2DM male patients and 35 age- and sex-matched 
control subjects were selected using a convenience sam-
pling technique based on the inclusion and exclusion 
criteria. The T2DM patients were newly diagnosed or 
follow-up cases on oral hypoglycemic drugs, including 
sulphonylureas and metformin. The control subjects 
did not have symptoms of any disease, were normal 
on clinical examination, were not on any medication, 
and had normal fasting plasma glucose (FPG). Both the 
groups had no clinical evidence of infectious, systemic, 
metabolic, and neuropsychiatric illnesses. The subjects 
in both the groups had no symptoms of peripheral 
neuropathy. The subjects were further examined clini-
cally for the intactness of sensations by testing for pain, 
light touch, position, stereognosia, graphesthesia, and 
extinction. The subjects with symptoms of peripheral 
neuropathy and abnormality in sensory examinations 
were excluded from the study. 
The participants were familiarized with the 
laboratory setting and the study design. All the par-
ticipants were informed of the potential risks and 
recording procedures, and informed written consent 
was obtained. They were interviewed using standard-
ized questionnaires for their medical history. Their 
detailed medical history, clinical examinations, and 
health status were documented using standard case 
history sheets. The recent reports on FPG, postpran-
dial glucose (PPG), and glycated hemoglobin (HbA1c) 
of the T2DM patients were noted. The FPG of control 
subjects was assessed and documented. The weight, 
height, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), respiratory rate (RR), heart rate (HR), 
and arterial oxygen saturation (SaO2%) of both the 
T2DM patients and control subjects were measured 
using standard tools and methods. Their body mass 
index (BMI, kg/m2) was calculated. The duration of 
diabetes in T2DM patients could not be reported 
because most of the patients included in the study 
were diagnosed of T2DM long after they started 
having features of DM. However, we reported the 
duration of diagnosis of DM in T2DM patients in 
years, though it was not possible to report the time 
duration precisely.
Sensory nerve conduction recording 
The temperature of the laboratory was maintained 
at 26 ± 2ºC. The subjects were advised to relax and 
their comfort was maintained before and during the 
recording procedures. The equipment used was a Digi-
tal Nihon Kohden machine (NM-4205, H636, Japan) 
and its accessories.
Each subject was asked to relax the limb during 
recording. Antidromic method of stimulation was fol-
lowed for studying sural NCS where the stimulation site 
was at the posterior lateral calf and the recording site 
was at the posterior ankle. Skinpure (skin purifier) was 
applied to clean the recording electrode site to reduce 
the skin impedance. A pair of recording electrodes 
was placed in line over the nerve at an inter-electrode 
distance of 3–4 cm, with the active recording electrode 
towards the side of the stimulating electrodes. Ground 
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electrode was placed between the recording and stimu-
lating electrodes. Surface stimulating electrode was 
used. The stimulating electrode was placed clearly on 
the sensory portion of nerve facing its cathode towards 
the recording electrodes.
Most sensory responses are very small (usually in 
the range of 1–50 μV). Hence, for sensory NCS, the gain 
is usually set at 10–20 μV per division as provided in 
the machine [10]. Stimulation parameters for sensory 
NCS as given in Table 1 were used.
An electrical pulse of 15 to 30 mA in the current 
range and 100 or 200 μsecs in duration was given to 
achieve supramaximal stimulation. The current was 
slowly increased from a baseline of 0 mA by 3–5 mA, 
until the recorded sensory nerve action potential was 
maximized. Each nerve was stimulated 20 times with 
supramaximal stimuli and the average was recorded. 
For each stimulation site the onset latency, amplitude, 
duration, and conduction velocity were measured. The 
normal cutoff values given in Table 2 were considered 
for sural SNAP. The T2DM patients with abnormal sural 
SNAPs were excluded from the study.
Statistical analysis
The data obtained were exported to the Statistical 
Package for the Social Sciences (SPSS version 24) and 
were tested for normal distribution. The data of age, 
weight, height, BMI, SBP, DBP, HR, RR, SaO2, blood 
sugar profile, and variables of bilateral sural SNAPs 
were normally distributed and expressed in terms of 
mean ± standard deviation. The unpaired t-test was 
used for comparison of all the variables between T2DM 
patients and control subjects. A p value of < 0.05 was 
considered statistically significant.
Results
There were no statistically significant differences in 
age, weight, height, BMI, SBP, DBP, HR, RR, and SaO2 
among the groups. The mean FPG of control subjects 
was significantly less (p = 0.000) compared to T2DM 
patients (Tab. 3). The PPG and HbA1C of T2DM patients 
were 13.42 ± 4.84 mmol/L and 6.79 ± 0.83% respec-
tively. The duration of diagnosis of DM in T2DM patients 
was 5.43 ± 2.56 years.
Latency, conduction velocity, amplitude, and duration 
of bilateral sural nerves were compared between T2DM pa-
tients and control subjects. The amplitudes of bilateral sural 
SNAPs were reduced (p < 0.05) in T2DM patients compared 
to control subjects (Table 4) though they were above the 
normal cutoff values of ≥ 4 μV (Tab. 2). In addition, there 
were prolonged durations of bilateral sural SNAPs in T2DM 
patients compared to control subjects (Tab. 4).
Discussion
The aim of this study was to assess electrophysi-
ological status of bilateral sural nerves in T2DM patients 
before they show the symptoms of peripheral neu-
ropathy. Our study revealed reduced amplitudes and 
prolonged durations of bilateral sural SNAPs in T2DM 
patients compared to control subjects.
Previous studies [12–14] have stated that the 
amplitude of the SNAP reflects the number of sen-
sory nerve axons and reduced SNAP amplitude is 
the primary abnormality associated with axonal loss. 
Comparing the amplitude of a potential with a normal 
control value is one of the best ways to assess the 
amount of axonal loss. One of the typical patterns as-
sociated with axonal loss is reduced amplitudes with 
preserved latencies and conduction velocities. Sensory 
amplitudes often are low in demyelinating lesions [12]. 
Table 1. Stimulus parameters for sensory nerve conduction 
studies [10]
Parameter
Sensory nerve  
conduction studies
Gain 20 μV per division
Time base 1 ms per division
Low-frequency filter 10 Hz
High-frequency filter 32 kHz
Stimulus duration 0.1 ms
 





Sural ≤ 4.2 ms at 14 cm ≥ 42 m/sec ≥ 4 μV
 
Table 3. Anthropometric, FPG, and cardio-respiratory 
 variables of T2DM and controls





Age (years) 53.67 ± 2.74 52.64 ± 3.25 0.156
Weight [kg] 63.75 ± 4.52 64.89 ± 4.72 0.307
Height [cm] 165.30 ± 6.07 166.99 ± 6.78 0.276
BMI [kg/m2] 23.36 ± 1.63 23.29 ± 1.43 0.846
FPG [mmol/L] 9.26 ± 2.67 5.05 ± 0.58 0.000
SBP [mm Hg] 118.80 ± 5.92 120.27 ± 5.72 0.293
DBP [mm Hg] 74.74 ± 4.80 74.06 ± 4.40 0.535
HR [beats/min] 79.46 ± 5.52 79.69 ± 6.92 0.881
RR [breaths/min] 13.58 ± 1.60 14.17 ± 2.15 0.199
SaO2 (%) 96.96 ± 1.44 97.22 ± 1.28 0.428
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These studies suggest the idea that the reduced am-
plitudes of bilateral sural SNAPs that we found in our 
study in T2DM patients compared to control subjects 
could be due to axonal loss, which often occurs in 
demyelinating disease.
In our study, we found prolonged durations of 
bilateral sural SNAPs in T2DM patients compared to 
the control subjects. The prolongation of sural SNAP 
duration is seen in polyneuropathies. However, the 
sural SNAP duration does not contribute to classifying 
polyneuropathies as axonal and demyelinating [15].
Sural nerve biopsies in diabetic patients with 
severe progressive neuropathy despite good blood 
glucose control have shown small vessel disease within 
the nerve [16]. Both ischemia and hypoxia are present 
in diabetic nerve in animals [17]. Impaired glucose 
tolerance (IGT) is a transitional state before diabetes 
and the dorsal sural nerve latencies are important 
for early detection of neuropathy. Sural nerve studies 
should be of value to determine neuropathy in IGT 
patients [18].
The amplitude of SNAP tends to be slightly higher 
in children due to lower skin impedance. After 60 years 
of age, NCV begins to slow slightly [10]. Aging deeply 
influences several morphological and functional fea-
tures of the PNS, affects functions, and electrophysio-
logical properties of the PNS, including reduced NCV, 
muscle strength, sensory discrimination, autonomic 
responses, and endoneural blood flow [19]. In our 
study, the mean age of T2DM patients is 53.67 ± 2.74 
years, which suggests that the age of the patients did 
not influence significantly the result of our study. The 
effect of aging (60 years) may be seen in our popula-
tion earlier than in western countries.
The increased BMI and lower sensory/mixed nerve 
amplitudes should be taken into account in clinical 
practice [20]. The NCV correlates more strongly with 
the height than with the age [21]. Height shows 
a significant correlation with most of the motor nerve 
conduction parameters and with a few sensory nerves 
[22]. However, in our study, the weight, height, and 
BMI were comparable between the groups.
We conducted our study in male population only, 
which avoided the variation in NCS due to sex differences. 
The SNAP latencies and duration are longer in males, 
whereas amplitude is higher in females. In addition, males 
have higher compound muscle action potential ampli-
tude, longer latencies, and duration than the females [23]. 
Thus, similar study on female population is suggested.
Sensory nerve response duration increases linearly 
with decline in skin temperature. The conduction ve-
locity for the fastest and slowest conducting sensory 
fibers increases non-linearly with an increase in skin 
temperature beyond the temperature range of 17–37°C 
[24]. In our study, we had maintained the temperature 
of the laboratory at 26 ± 2ºC, which prevented varia-
tion in the NCS due to temperature.
Abnormality in NCS in diabetic neuropathy appears 
earlier than clinical symptoms and signs without small 
fiber neuropathy. Therefore, NCS is important in the 
early detection of diabetic neuropathy [25].
We found reduced amplitudes and prolonged 
durations of bilateral sural SNAPs in T2DM patients 
compared to control subjects, although T2DM patients 
did not show overt peripheral neuropathy. Hence, we 
concluded that electrophysiological alterations sug-
gestive of peripheral neuropathy occur in patients 
with T2DM before they show any clinical features of 
peripheral neuropathy. Early detection of peripheral 
neuropathy in T2DM patients enables clinicians to help 
prevent long-term complications of diabetes mellitus 
such as foot ulcers and amputations.
Our study did not include more than one test 
modalities and could not evaluate the status of all the 
vulnerable sensory, motor, and mixed peripheral nerves. 
Future studies should compare nerve conduction vari-




T2DM (n = 35) Control subjects (n = 35)
Latency [ms]
Left 2.42 ± 0.36 2.39 ± 0.45 0.766
Right 2.48 ± 0.37 2.40 ± 0.32 0.311
Conduction velocity [m/s]
Left 56.30 ± 5.09 57.33 ± 10.41 0.603
Right 58.06 ± 9.30 59.08 ± 8.40 0.632
Amplitude [μV]
Left 12.46 ± 3.77 16.42 ± 4.58 0.000
Right 11.96 ± 4.45 16.62 ± 6.20 0.001
Duration [ms]
Left 1.99 ± 0.38 1.67 ± 0.27 0.000
Right 1.92 ± 0.47 1.55 ± 0.33 0.000
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ables of the other vulnerable sensory, motor, and mixed 
peripheral nerves along with sural nerve (including 
evaluation of small fiber neuropathy, e.g. fibers for 
temperature sensation) among diabetic patients with 
symptomatic peripheral neuropathy, diabetic patients 
without symptoms of peripheral neuropathy, and 
control subjects.
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